Improving Treatment-Related Symptom Management in Adolescents and Young Adults With Cancer

University of California, Davis20 enrolled

Overview

This study will test the acceptability and feasibility of a telehealth intervention to improve communication between patients and medical providers in adolescent and young adult (AYA) cancer patients receiving chemotherapy treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cancer

Interventions

Telehealth visitsBEHAVIORAL

Receiving telehealth visits with a medical provider (MD or NP) 2-3 days after last chemotherapy administration in the cycle

Standard of CareBEHAVIORAL

Receiving care as usual from the UC Davis Comprehensive Cancer Center

Eligibility

Sex: ALLMin age: 12 YearsMax age: 29 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with cancer undergoing active treatment and who have received at least two cycles of chemotherapy * Access to Epic MyChart (we will facilitate access to MyChart for interested patients who are not yet signed up) * Access to a smartphone or tablet to access EPIC MyChart telehealth appointments Exclusion Criteria: * Non-English or non-Spanish speaking patients * Potentially completing therapy during study period (including follow-up period) or plans to leave UCDCCC during study period

Locations (1)

Comprehensive Cancer Center

Sacramento, California, United States

Outcomes

Primary Outcomes

Proportion of Patients Completing the Trial

\>65% of enrolled patients will complete the trial

Time frame: end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)

Secondary Outcomes

Survey Response Rate

\>%70% of enrolled patients will complete the survey instruments

Time frame: end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)

Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ)

A composite score of ≥40 (based on 10 items with a Likert scale of 1-5 strongly disagree to strongly agree)

Time frame: end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.